DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specific antibodies are generally poor inducers of CDC. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Oostindie, Simone C., van der Horst, Hilma J., Kil, Laurens P., Strumane, Kristin, Overdijk, Marije B., van den Brink, Edward N., van den Brakel, Jeroen H. N., Rademaker, Hendrik J., van Kessel, Berris, van den Noort, Juliette, Chamuleau, Martine E. D., Mutis, Tuna, Lindorfer, Margaret A., Taylor, Ronald P., Schuurman, Janine, Parren, Paul W. H. I., Beurskens, Frank J., Breij, Esther C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186228/
https://www.ncbi.nlm.nih.gov/pubmed/32341336
http://dx.doi.org/10.1038/s41408-020-0292-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186228/
https://www.ncbi.nlm.nih.gov/pubmed/32341336
http://dx.doi.org/10.1038/s41408-020-0292-7

Ejemplares similares